Andrea Flynn - Vice President and Head-Investor Relations

Bruce Cozadd - Chairman and Chief Executive Officer

Renée Galá - President and Chief Operating Officer

Rob Iannone - Executive Vice President and Global Head-R&D

Phil Johnson - Executive Vice President and Chief Financial Officer

Ladies and gentlemen. Thank you for standing by. My name is Abbie, and I'll be your operator today. At this time, I would like to welcome everyone to the Jazz Pharmaceuticals Third Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background. After the speakers' remarks there will be a question-and-answer session. [Operator Instructions] Thank you.

I would now like to turn the conference over to Andrea Flynn, Vice President and Head of Investor Relations. You may begin.

Andrea Flynn

Thank you, operator, and good afternoon, everyone Today, Jazz Pharmaceuticals reported its third quarter 2024 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website.

On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renée Galá, President and Chief Operating Officer; Rob Iannone, Executive Vice President and Global Head of R&D; and Phil Johnson, Chief Financial Officer.

On Slide 2, I'd like to remind you that today's webcast includes forward-looking statements, such as those related to our